A new study by UT Southwestern INFIRMARY cancer researchers finds.

‘We found that pemetrexed combined with cisplatin is much less toxic, well tolerated, and really should be developed for further treatment of cervical malignancy,’ said gynecologic oncology professional Dr. David Miller, Professor of Obstetrics and Gynecology and a known member of the Harold C. Simmons Cancer Center. In the Stage II scientific trial, Dr. Miller and colleagues in the National Cancer Institute -supported Gynecologic Oncology Group found that in patients who had not received prior chemotherapy, the combination cocktail had a 31 % response rate for to 7 months up, and an overall survival of 12 months.Louis report on the web this week in Science Express. They found that orexin also, a protein that helps regulate the sleep cycle, appears to be directly involved in the increase. Neurodegenerative disorders like Alzheimer’s disease and Parkinson’s disease frequently disrupt sleep. The new findings are some of the first indications that sleep reduction could are likely involved in the genesis of such disorders. ‘Orexin or compounds it interacts with could become new drug targets for treatment of Alzheimer’s disease,’ says senior author David M.